Top

Molecular Neurodegeneration

Published in:

Open Access 01-12-2010 | Research article

Endocytic pathways mediating oligomeric Aβ42 neurotoxicity

Authors: Chunjiang Yu, Evelyn Nwabuisi-Heath, Kevin Laxton, Mary Jo LaDu

Published in: Molecular Neurodegeneration | Issue 1/2010

Abstract

Background

One pathological hallmark of Alzheimer's disease (AD) is amyloid plaques, composed primarily of amyloid-β peptide (Aβ). Over-production or diminished clearance of the 42 amino acid form of Aβ (Aβ42) in the brain leads to accumulation of soluble Aβ and plaque formation. Soluble oligomeric Aβ (oAβ) has recently emerged to be as a likely proximal cause of AD.

Results

Here we demonstrate that endocytosis is critical in mediating oAβ42-induced neurotoxicity and intraneuronal accumulation of Aβ. Inhibition of clathrin function either with a pharmacological inhibitor, knock-down of clathrin heavy chain expression, or expression of the dominant-negative mutant of clathrin-assembly protein AP180 did not block oAβ42-induced neurotoxicity or intraneuronal accumulation of Aβ. However, inhibition of dynamin and RhoA by expression of dominant negative mutants reduced neurotoxicity and intraneuronal Aβ accumulation. Pharmacologic inhibition of the dynamin-mediated endocytic pathway by genistein also reduced neurotoxicity.

Conclusions

These data suggest that dynamin-mediated and RhoA-regulated endocytosis are integral steps for oligomeric Aβ42-induced neurotoxicity and intraneuronal Aβ accumulation.

Available only for authorised users

Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992, 256 (5054): 184-185. 10.1126/science.1566067.PubMedCrossRef

Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE: Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996, 271 (8): 4077-4081. 10.1074/jbc.271.8.4077.PubMedCrossRef

McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL: Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999, 46 (6): 860-866. 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M.PubMedCrossRef

Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR: Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem. 1996, 271 (34): 20631-20635. 10.1074/jbc.271.34.20631.PubMedCrossRef

Funato H, Enya M, Yoshimura M, Morishima-Kawashima M, Ihara Y: Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am J Pathol. 1999, 155 (1): 23-28.PubMedPubMedCentralCrossRef

Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006, 440 (7082): 352-357. 10.1038/nature04533.PubMedCrossRef

Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002, 416 (6880): 535-539. 10.1038/416535a.PubMedCrossRef

Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. American Journal Of Pathology. 1999, 155 (3): 853-862.PubMedPubMedCentralCrossRef

Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L: High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000, 20 (11): 4050-4058.PubMed

10.

Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD: Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Jama. 2000, 283 (12): 1571-1577. 10.1001/jama.283.12.1571.PubMedCrossRef

11.

Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT: Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005, 25 (31): 7278-7287. 10.1523/JNEUROSCI.1879-05.2005.PubMedPubMedCentralCrossRef

12.

Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML: Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 2004, 33 (3): 377-387. 10.1023/B:NEUR.0000044197.83514.64.PubMedCrossRef

13.

Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ: The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000, 39 (35): 10831-10839. 10.1021/bi001048s.PubMedCrossRef

14.

Podlisny MB, Walsh DM, Amarante P, Ostaszewski BL, Stimson ER, Maggio JE, Teplow DB, Selkoe DJ: Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry. 1998, 37 (11): 3602-3611. 10.1021/bi972029u.PubMedCrossRef

15.

Harper JD, Wong SS, Lieber CM, Lansbury PT: Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol. 1997, 4 (2): 119-125. 10.1016/S1074-5521(97)90255-6.PubMedCrossRef

16.

Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ: Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 1999, 19 (20): 8876-8884.PubMed

17.

Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL: Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998, 95 (11): 6448-6453. 10.1073/pnas.95.11.6448.PubMedPubMedCentralCrossRef

18.

Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ: Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002, 277 (35): 32046-32053. 10.1074/jbc.M201750200.PubMedCrossRef

19.

Stine WB, Dahlgren KN, Krafft GK, LaDu MJ: In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003, 278: 11612-11622. 10.1074/jbc.M210207200.PubMedCrossRef

20.

Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003, 300 (5618): 486-489. 10.1126/science.1079469.PubMedCrossRef

21.

Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG: Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007, 2: 18-10.1186/1750-1326-2-18.PubMedPubMedCentralCrossRef

22.

Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB: Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997, 272 (35): 22364-22372. 10.1074/jbc.272.35.22364.PubMedCrossRef

23.

Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H: Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. Journal of neurochemistry. 2005, 95 (3): 834-847. 10.1111/j.1471-4159.2005.03407.x.PubMedCrossRef

24.

Ono K, Condron MM, Teplow DB: Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proceedings of the National Academy of Sciences of the United States of America. 2009, 106 (35): 14745-14750. 10.1073/pnas.0905127106.PubMedPubMedCentralCrossRef

25.

Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007, 8 (2): 101-112. 10.1038/nrm2101.PubMedCrossRef

26.

Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK: Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis. 2005, 20 (2): 187-198. 10.1016/j.nbd.2005.02.008.PubMedCrossRef

27.

Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P: Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005, 8 (8): 1051-1058. 10.1038/nn1503.PubMedCrossRef

28.

Chang EH, Savage MJ, Flood DG, Thomas JM, Levy RB, Mahadomrongkul V, Shirao T, Aoki C, Huerta PT: AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proceedings of the National Academy of Sciences of the United States of America. 2006, 103 (9): 3410-3415. 10.1073/pnas.0507313103.PubMedPubMedCentralCrossRef

29.

Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R: AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006, 52 (5): 831-843. 10.1016/j.neuron.2006.10.035.PubMedPubMedCentralCrossRef

30.

Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guilloz Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL, et al: Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA. 2003

31.

D'Andrea MR, Reiser PA, Polkovitch DA, Gumula NA, Branchide B, Hertzog BM, Schmidheiser D, Belkowski S, Gastard MC, Andrade-Gordon P: The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observations. Neurosci Lett. 2003, 342 (1-2): 114-118. 10.1016/S0304-3940(03)00252-0.PubMedCrossRef

32.

D'Andrea MR, Nagele RG, Wang HY, Lee DH: Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex. Neurosci Lett. 2002, 333 (3): 163-166. 10.1016/S0304-3940(02)00875-3.PubMedCrossRef

33.

Grundke-Iqbal I, Iqbal K, George L, Tung YC, Kim KS, Wisniewski HM: Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci USA. 1989, 86 (8): 2853-2857. 10.1073/pnas.86.8.2853.PubMedPubMedCentralCrossRef

34.

LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, Jay G: Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest. 1997, 100 (2): 310-320. 10.1172/JCI119536.PubMedPubMedCentralCrossRef

35.

Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK: Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002, 161 (5): 1869-1879.PubMedPubMedCentralCrossRef

36.

Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA: Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid. 2002, 9 (2): 88-102.PubMed

37.

Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC: Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med. 2001, 125 (4): 489-492.PubMed

38.

Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, Yankner BA: Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron. 2002, 33 (5): 677-688. 10.1016/S0896-6273(02)00604-9.PubMedCrossRef

39.

Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR: Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000, 156 (1): 15-20.PubMedPubMedCentralCrossRef

40.

Langui D, Girardot N, El Hachimi KH, Allinquant B, Blanchard V, Pradier L, Duyckaerts C: Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am J Pathol. 2004, 165 (5): 1465-1477.PubMedPubMedCentralCrossRef

41.

D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH: Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology. 2001, 38 (2): 120-134. 10.1046/j.1365-2559.2001.01082.x.PubMedCrossRef

42.

Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA: Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett. 2001, 306 (1-2): 116-120. 10.1016/S0304-3940(01)01876-6.PubMedCrossRef

43.

Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM: Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003, 39 (3): 409-421. 10.1016/S0896-6273(03)00434-3.PubMedCrossRef

44.

Shie FS, LeBoeuf RC, Jin LW: Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice. Neuroreport. 2003, 14 (1): 123-129. 10.1097/00001756-200301200-00023.PubMedCrossRef

45.

Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK: Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004, 24 (14): 3592-3599. 10.1523/JNEUROSCI.5167-03.2004.PubMedCrossRef

46.

Skovronsky DM, Doms RW, Lee VM: Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol. 1998, 141 (4): 1031-1039. 10.1083/jcb.141.4.1031.PubMedPubMedCentralCrossRef

47.

Mazur-Kolecka B, Frackowiak J, Carroll RT, Wisniewski HM: Accumulation of Alzheimer amyloid-beta peptide in cultured myocytes is enhanced by serum and reduced by cerebrospinal fluid. J Neuropathol Exp Neurol. 1997, 56 (3): 263-272. 10.1097/00005072-199703000-00005.PubMedCrossRef

48.

Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, Kolk van der N, Vingtdeux V, Steeg van de E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L: Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol. 2004, 165 (4): 1289-1300.PubMedPubMedCentralCrossRef

49.

Mochizuki A, Tamaoka A, Shimohata A, Komatsuzaki Y, Shoji S: Abeta42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease. Lancet. 2000, 355 (9197): 42-43. 10.1016/S0140-6736(99)04937-5.PubMedCrossRef

50.

Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, Laferla FM: Temporal profile of Abeta oligomerization in an in vivo model of Alzheimer's disease: A link between Abeta and tau pathology. J Biol Chem. 2005

51.

Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG: Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2004, 24 (15): 3801-3809. 10.1523/JNEUROSCI.5543-03.2004.PubMedCrossRef

52.

Oshima N, Morishima-Kawashima M, Yamaguchi H, Yoshimura M, Sugihara S, Khan K, Games D, Schenk D, Ihara Y: Accumulation of amyloid beta-protein in the low-density membrane domain accurately reflects the extent of beta-amyloid deposition in the brain. Am J Pathol. 2001, 158 (6): 2209-2218.PubMedPubMedCentralCrossRef

53.

Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F: Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999, 274 (10): 6483-6492. 10.1074/jbc.274.10.6483.PubMedCrossRef

54.

Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L: Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA. 1999, 96 (6): 3228-3233. 10.1073/pnas.96.6.3228.PubMedPubMedCentralCrossRef

55.

Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TVP, Hyman BT, Younkin SG, Hsiao KK: Impaired synpatic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Genet. 1999, 2: 271-276.

56.

Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, Bu G: Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. The Journal of biological chemistry. 2006, 281 (47): 36180-36186. 10.1074/jbc.M604436200.PubMedCrossRef

57.

Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004, 43 (3): 321-332. 10.1016/j.neuron.2004.07.003.PubMedCrossRef

58.

Billings LM, Oddo S, Green KN, McGaugh JL, Laferla FM: Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005, 45 (5): 675-688. 10.1016/j.neuron.2005.01.040.PubMedCrossRef

59.

Gimenez-Llort L, Blazquez G, Canete T, Johansson B, Oddo S, Tobena A, Laferla FM, Fernandez-Teruel A: Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: A role for intraneuronal amyloid. Neurosci Biobehav Rev. 2006, 31 (1): 125-147. 10.1016/j.neubiorev.2006.07.007.PubMedCrossRef

60.

Shie FS, LeBoeuf RC, Jin LW: Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice.[erratum appears in Neuroreport. 2004 Aug 26;15(12):1993 Note: LeBoeur, Renee C [corrected to LeBoeuf, Renee C]]. Neuroreport. 2003, 14 (1): 123-129. 10.1097/00001756-200301200-00023.PubMedCrossRef

61.

Glabe C: Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J Mol Neurosci. 2001, 17 (2): 137-145. 10.1385/JMN:17:2:137.PubMedCrossRef

62.

Knauer MF, Soreghan B, Burdick D, Kosmoski J, Glabe CG: Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc Natl Acad Sci USA. 1992, 89 (16): 7437-7441. 10.1073/pnas.89.16.7437.PubMedPubMedCentralCrossRef

63.

Burdick D, Kosmoski J, Knauer MF, Glabe CG: Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, A beta 1-42, in differentiated PC12 cells. Brain Res. 1997, 746 (1-2): 275-284. 10.1016/S0006-8993(96)01262-0.PubMedCrossRef

64.

Bahr BA, Hoffman KB, Yang AJ, Hess US, Glabe CG, Lynch G: Amyloid beta protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J Comp Neurol. 1998, 397 (1): 139-147. 10.1002/(SICI)1096-9861(19980720)397:1<139::AID-CNE10>3.0.CO;2-K.PubMedCrossRef

65.

Jungbauer LM, Yu C, Laxton KJ, LaDu MJ: Preparation of fluorescently-labeled amyloid-beta peptide assemblies: the effect of fluorophore conjugation on structure and function. J Mol Recognit. 2009, 22 (5): 403-413. 10.1002/jmr.948.PubMedPubMedCentralCrossRef

66.

Zhang Y, McLaughlin R, Goodyer C, LeBlanc A: Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002, 156 (3): 519-529. 10.1083/jcb.200110119.PubMedPubMedCentralCrossRef

67.

Pigino G, Morfini G, Atagi Y, Deshpande A, Yu C, Jungbauer L, LaDu M, Busciglio J, Brady S: Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci USA. 2009, 106 (14): 5907-5912. 10.1073/pnas.0901229106.PubMedPubMedCentralCrossRef

68.

Manelli AM, Bulfinch LC, Sullivan PM, LaDu MJ: Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol Aging. 2007, 28 (8): 1139-1147. 10.1016/j.neurobiolaging.2006.05.024.PubMedPubMedCentralCrossRef

69.

Manelli AM, Stine WB, Van Eldik LJ, LaDu MJ: ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci. 2004, 23 (3): 235-246. 10.1385/JMN:23:3:235.PubMedCrossRef

70.

Trommer BL, Shah C, Yun SH, Gamkrelidze G, Pasternak ES, Stine WB, Manelli A, Sullivan P, Pasternak JF, LaDu MJ: ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. Neurobiology of disease. 2005, 18 (1): 75-82. 10.1016/j.nbd.2004.08.011.PubMedCrossRef

71.

Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, Sherman MA, Lesne S, Ladu MJ, Walsh DM, Ashe KH, Cleary JP: Cognitive effects of cell-derived and synthetically derived Abeta oligomers. Neurobiology of aging. 2009

72.

White JA, Manelli AM, Holmberg KH, Van Eldik LJ, LaDu MJ: Differential effects of oligomeric and fibrillar amyloid-beta1-42 on astrocyte-mediated inflammation. Neurobiol Dis. 2005, 18 (3): 459-465. 10.1016/j.nbd.2004.12.013.PubMedCrossRef

73.

Zhao X, Greener T, Al-Hasani H, Cushman SW, Eisenberg E, Greene LE: Expression of auxilin or AP180 inhibits endocytosis by mislocalizing clathrin: evidence for formation of nascent pits containing AP1 or AP2 but not clathrin. J Cell Sci. 2001, 114 (Pt 2): 353-365.PubMed

74.

Ford MG, Pearse BM, Higgins MK, Vallis Y, Owen DJ, Gibson A, Hopkins CR, Evans PR, McMahon HT: Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science (New York, NY). 2001, 291 (5506): 1051-1055.CrossRef

75.

Wang LH, Rothberg KG, Anderson RG: Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol. 1993, 123 (5): 1107-1117. 10.1083/jcb.123.5.1107.PubMedCrossRef

76.

Mayor S, Pagano RE: Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol. 2007, 8 (8): 603-612. 10.1038/nrm2216.PubMedCrossRef

77.

Zeng H, Chen Q, Zhao B: Genistein ameliorates beta-amyloid peptide (25-35)-induced hippocampal neuronal apoptosis. Free Radic Biol Med. 2004, 36 (2): 180-188. 10.1016/j.freeradbiomed.2003.10.018.PubMedCrossRef

78.

Bang OY, Hong HS, Kim DH, Kim H, Boo JH, Huh K, Mook-Jung I: Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. Neurobiol Dis. 2004, 16 (1): 21-28. 10.1016/j.nbd.2003.12.017.PubMedCrossRef

79.

Damke H, Baba T, Warnock DE, Schmid SL: Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol. 1994, 127 (4): 915-934. 10.1083/jcb.127.4.915.PubMedCrossRef

80.

Pan ZK, Ye RD, Christiansen SC, Jagels MA, Bokoch GM, Zuraw BL: Role of the Rho GTPase in bradykinin-stimulated nuclear factor-kappaB activation and IL-1beta gene expression in cultured human epithelial cells. Journal of immunology (Baltimore, Md). 1998, 160 (6): 3038-3045.

81.

Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, et al: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009, 41 (10): 1088-1093. 10.1038/ng.440.PubMedPubMedCentralCrossRef

82.

Bushlin I, Petralia RS, Wu F, Harel A, Mughal MR, Mattson MP, Yao PJ: Clathrin assembly protein AP180 and CALM differentially control axogenesis and dendrite outgrowth in embryonic hippocampal neurons. J Neurosci. 2008, 28 (41): 10257-10271. 10.1523/JNEUROSCI.2471-08.2008.PubMedPubMedCentralCrossRef

83.

Mousavi SA, Malerod L, Berg T, Kjeken R: Clathrin-dependent endocytosis. Biochem J. 2004, 377 (Pt 1): 1-16. 10.1042/BJ20031000.PubMedPubMedCentralCrossRef

84.

Yao PJ, Morsch R, Callahan LM, Coleman PD: Changes in synaptic expression of clathrin assembly protein AP180 in Alzheimer's disease analysed by immunohistochemistry. Neuroscience. 1999, 94 (2): 389-394. 10.1016/S0306-4522(99)00360-7.PubMedCrossRef

85.

Small SA, Gandy S: Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron. 2006, 52 (1): 15-31. 10.1016/j.neuron.2006.09.001.PubMedCrossRef

86.

Kirkham M, Parton RG: Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta. 2005, 1745 (3): 273-286. 10.1016/j.bbamcr.2005.06.002.PubMedCrossRef

87.

Saavedra L, Mohamed A, Ma V, Kar S, de Chaves EP: Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. The Journal of biological chemistry. 2007, 282 (49): 35722-35732. 10.1074/jbc.M701823200.PubMedCrossRef

88.

Lamaze C, Dujeancourt A, Baba T, Lo CG, Benmerah A, Dautry-Varsat A: Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. Mol Cell. 2001, 7 (3): 661-671. 10.1016/S1097-2765(01)00212-X.PubMedCrossRef

89.

Huesa G, Baltrons MA, Gomez-Ramos P, Moran A, Garcia A, Hidalgo J, Frances S, Santpere G, Ferrer I, Galea E: Altered Distribution of RhoA in Alzheimer's Disease and AbetaPP Overexpressing Mice. J Alzheimers Dis. 2009, 19 (1): 37-56.

90.

Petratos S, Li QX, George AJ, Hou X, Kerr ML, Unabia SE, Hatzinisiriou I, Maksel D, Aguilar MI, Small DH: The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. Brain. 2008, 131 (Pt 1): 90-108.PubMed

91.

Shyng SL, Heuser JE, Harris DA: A glycolipid-anchored prion protein is endocytosed via clathrin-coated pits. J Cell Biol. 1994, 125 (6): 1239-1250. 10.1083/jcb.125.6.1239.PubMedCrossRef

92.

Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF: Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. PLoS One. 2009, 4 (2): e4627-10.1371/journal.pone.0004627.PubMedPubMedCentralCrossRef

93.

Abe K, Sekizawa T, Kogure K: Biphasic effects of chlorpromazine on cell viability in a neuroblastoma cell line. Neurosci Lett. 1986, 71 (3): 335-339. 10.1016/0304-3940(86)90643-9.PubMedCrossRef

94.

Gyllberg H, Lofgren K, Lindegren H, Bedecs K: Increased Src kinase level results in increased protein tyrosine phosphorylation in scrapie-infected neuronal cell lines. FEBS Lett. 2006, 580 (11): 2603-2608. 10.1016/j.febslet.2006.03.092.PubMedCrossRef

Title: Endocytic pathways mediating oligomeric Aβ42 neurotoxicity
Authors: Chunjiang Yu
Evelyn Nwabuisi-Heath
Kevin Laxton
Mary Jo LaDu
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Molecular Neurodegeneration / Issue 1/2010
Electronic ISSN: 1750-1326
DOI: https://doi.org/10.1186/1750-1326-5-19

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Endocytic pathways mediating oligomeric Aβ42 neurotoxicity

Abstract

Background

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Wnt-5aoccludes Aβ oligomer-induced depression of glutamatergic transmission in hippocampal neurons

Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease

Aberrant ERK 1/2 complex activation and localization in scrapie-infected GT1-1 cells

Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model

Axotomy-induced neurotrophic withdrawal causes the loss of phenotypic differentiation and downregulation of NGF signalling, but not death of septal cholinergic neurons

The biochemical aftermath of anti-amyloid immunotherapy